<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01905553</url>
  </required_header>
  <id_info>
    <org_study_id>SPD602-113</org_study_id>
    <nct_id>NCT01905553</nct_id>
  </id_info>
  <brief_title>The Effect of Food on the Bioavailability of a Single Dose of SSP-004184SS in Healthy Adult Subjects</brief_title>
  <official_title>A Phase 1, Open-label, Randomized, 2-period, Crossover, Exploratory Study to Investigate the Effect of Food on the Bioavailability of a Single Dose of SSP-004184SS in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the effect of food on the pharmacokinetic profile of SSP-004184 compared to&#xD;
      administration under fasted conditions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 27, 2013</start_date>
  <completion_date type="Actual">September 24, 2013</completion_date>
  <primary_completion_date type="Actual">September 24, 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUCinf) of SSP-004184 Under Fasted and Fed Conditions</measure>
    <time_frame>Study Periods 1 &amp; 2: Within 30 minutes pre-dose, and Post-dose 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 48, 72 hours.</time_frame>
    <description>AUCinf is the area under the plasma concentration versus time curve from time 0 to infinity. AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measureable Concentration (AUClast) of SSP-004184 Under Fed and Fasted Conditions</measure>
    <time_frame>Study Periods 1 &amp; 2: Within 30 minutes pre-dose, and Post-dose 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 48, 72 hours.</time_frame>
    <description>AUClast is the area under the curve from the time of dosing to the last measurable concentration. AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of SSP-004184 Under Fed and Fasted Conditions</measure>
    <time_frame>Study Periods 1 &amp; 2: Within 30 minutes pre-dose, and Post-dose 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 48, 72 hours.</time_frame>
    <description>Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>SSP-004184SS (fed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>21.8 mg/kg (oral capsule form) given once on Day 1 under fed conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SSP-004184SS (fasted)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>21.8 mg/kg (oral capsule form) given once on Day 1 under fasted conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SSP-004184SS</intervention_name>
    <description>Disodium salt</description>
    <arm_group_label>SSP-004184SS (fasted)</arm_group_label>
    <arm_group_label>SSP-004184SS (fed)</arm_group_label>
    <other_name>SPD602</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-65 years inclusive at the time of consent. The date of signing informed consent&#xD;
             is defined as the beginning of the Screening Period. This inclusion criterion will&#xD;
             only be assessed at the Screening Visit.&#xD;
&#xD;
          -  Subject is considered &quot;healthy&quot;. Healthy status is defined by absence of evidence of&#xD;
             any active or chronic disease following a detailed medical and surgical history, a&#xD;
             complete physical examination including vital signs, 12-lead ECG, hematology, blood&#xD;
             chemistry, and urinalysis.&#xD;
&#xD;
          -  Serum ferritin &gt;20ng/mL, hemoglobin &gt;125g/l, and erythrocyte indices within normal&#xD;
             range of the clinical laboratory at the Screening Visit and on Day -1: packed cell&#xD;
             volume, mean corpuscular volume, and mean corpuscular hemoglobin concentration, or&#xD;
             deemed not clinically significant by the investigator.&#xD;
&#xD;
          -  Subject is willing to comply with any applicable contraceptive requirements of the&#xD;
             protocol and is:&#xD;
&#xD;
          -  Male, or&#xD;
&#xD;
          -  Female of non-childbearing potential (defined as a female who is post-menopausal&#xD;
             [amenorrhea for at least 12 consecutive months] or surgically sterile [hysterectomy,&#xD;
             bilateral tubal ligation, bilateral oophorectomy, or bilateral salpingectomy]) and at&#xD;
             least 6 weeks post-sterilization&#xD;
&#xD;
          -  Non-pregnant, non-lactating female&#xD;
&#xD;
          -  At least 90 days post-partum or nulliparous (females only).&#xD;
&#xD;
          -  An understanding, ability, and willingness to fully comply with study procedures and&#xD;
             restrictions.&#xD;
&#xD;
          -  Ability to provide written, personally signed, and dated informed consent to&#xD;
             participate in the study, in accordance with International Conference on Harmonisation&#xD;
             Good Clinical Practice Guideline E6 (1996) and applicable regulations, before&#xD;
             completing any study-related procedures.&#xD;
&#xD;
          -  Body mass index between 18.5-30.0kg/mÂ² inclusive. This inclusion criterion will be&#xD;
             assessed only at the Screening Visit.&#xD;
&#xD;
          -  Ability to swallow the investigational product (multiple capsules at 1 time or&#xD;
             consecutively 1 capsule at a time).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A clinically significant history or disorder detected during the medical&#xD;
             interview/physical examination such as any cardiovascular, bronchopulmonary,&#xD;
             gastrointestinal (eg, inflammatory bowel disease, chronic diarrhea), hepatic, biliary&#xD;
             (including gall bladder removal), renal, hematological, endocrine, autoimmune,&#xD;
             neurological, or psychiatric disease (including depression) or any other medical&#xD;
             condition that is capable of altering the absorption, metabolism, or elimination of&#xD;
             drugs; or of constituting a risk factor when taking the investigational product in the&#xD;
             judgment of the investigator.&#xD;
&#xD;
          -  Confirmed systolic blood pressure &gt;139mmHg or &lt;89mmHg, and diastolic blood pressure&#xD;
             &gt;89mmHg or &lt;49mmHg.&#xD;
&#xD;
          -  Twelve-lead ECG demonstrating QTc &gt;450msec at screening. If QTc exceeds 450msec, the&#xD;
             ECG should be repeated 2 more times and the average of the 3 QTc values should be used&#xD;
             to determine the subject's eligibility.&#xD;
&#xD;
          -  Subject reports any food allergies, celiac disease, or requirements for specific diet&#xD;
             (eg, vegan, vegetarian, low fat).&#xD;
&#xD;
          -  Acute illness, as judged by the investigator, within 2 weeks of Day 1 of Treatment&#xD;
             Period 1.&#xD;
&#xD;
          -  Known or suspected intolerance or hypersensitivity to the investigational products,&#xD;
             closely related compounds, or any of the stated ingredients.&#xD;
&#xD;
          -  History of thyroid disorder that has not been stabilized on thyroid medication or&#xD;
             treatment within 3 months of the Screening Visit.&#xD;
&#xD;
          -  History of alcohol or other substance abuse within the last year.&#xD;
&#xD;
          -  Routine consumption of more than 3 units of caffeine per day or subjects who&#xD;
             experience caffeine withdrawal headaches.&#xD;
&#xD;
          -  A positive screen for alcohol or drugs of abuse at the Screening Visit.&#xD;
&#xD;
          -  Male subjects who consume more than 3 units of alcohol per day. Female subjects who&#xD;
             consume more than 2 units of alcohol per day.&#xD;
&#xD;
          -  A positive human immunodeficiency virus antibody screen, hepatitis B surface antigen&#xD;
             screen, or hepatitis C virus antibody screen.&#xD;
&#xD;
          -  Current use of any other medication (including over-the-counter, herbal, or&#xD;
             homeopathic preparations) that could affect (improve or worsen) the study evaluations&#xD;
             according to the investigator.&#xD;
&#xD;
          -  Use of tobacco in any form (eg, smoking or chewing) or other nicotine-containing&#xD;
             products in any form (eg, gum, patch) within 30 days prior to Day 1 of Treatment&#xD;
             Period 1.&#xD;
&#xD;
          -  Donation of blood or blood products (eg, plasma or platelets) within 60 days prior to&#xD;
             Day 1 of Treatment Period 1.&#xD;
&#xD;
          -  Use of another investigational product within 30 days prior to Day 1 of Treatment&#xD;
             Period 1 or active enrollment in another drug or vaccine clinical study.&#xD;
&#xD;
          -  Substantial changes in eating habits within 30 days prior to Day 1 of Treatment Period&#xD;
             1, as assessed by the investigator.&#xD;
&#xD;
          -  Prior screen failure, randomization, participation, or enrollment in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 18, 2013</study_first_submitted>
  <study_first_submitted_qc>July 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2013</study_first_posted>
  <results_first_submitted>December 16, 2014</results_first_submitted>
  <results_first_submitted_qc>December 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 24, 2014</results_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SSP-004184SS Fed First</title>
          <description>Subjects received a single dose SSP-004184SS 21.8mg/kg on Day 1 administered 30 minutes after starting a standard high-fat, high-calorie breakfast in Treatment Period 1. During Treatment Period 2, subjects received a single-dose administration of 21.8mg/kg of SSP-004184SS under fasted conditions.</description>
        </group>
        <group group_id="P2">
          <title>SSP-004184SS Fasted First</title>
          <description>Subjects received a single-dose administration of 21.8mg/kg of SSP-004184SS under fasted conditions on Day 1 in Treatment Period 1. During Treatment Period 2, subjects received a single dose SSP-004184SS 21.8mg/kg on Day 1 administered 30 minutes after starting a standard high-fat, high-calorie breakfast.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Safety Set consists of all subjects who have taken at least 1 dose of investigational product and have at least 1 post-dose safety assessment.</population>
      <group_list>
        <group group_id="B1">
          <title>SSP-004184SS Fed First</title>
          <description>Subjects received a single dose SSP-004184SS 21.8mg/kg on Day 1 administered 30 minutes after starting a standard high-fat, high-calorie breakfast in Treatment Period 1. During Treatment Period 2, subjects received a single-dose administration of 21.8mg/kg of SSP-004184SS under fasted conditions.</description>
        </group>
        <group group_id="B2">
          <title>SSP-004184SS Fasted First</title>
          <description>Subjects received a single-dose administration of 21.8mg/kg of SSP-004184SS under fasted conditions on Day 1 in Treatment Period 1. During Treatment Period 2, subjects received a single dose SSP-004184SS 21.8mg/kg on Day 1 administered 30 minutes after starting a standard high-fat, high-calorie breakfast.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42" spread="10.89"/>
                    <measurement group_id="B2" value="35" spread="7.62"/>
                    <measurement group_id="B3" value="38.9" spread="9.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>UNITED STATES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUCinf) of SSP-004184 Under Fasted and Fed Conditions</title>
        <description>AUCinf is the area under the plasma concentration versus time curve from time 0 to infinity. AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.</description>
        <time_frame>Study Periods 1 &amp; 2: Within 30 minutes pre-dose, and Post-dose 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 48, 72 hours.</time_frame>
        <population>Pharmacokinetic Set: All subjects in the Safety Set for whom the primary pharmacokinetic data were considered sufficient and interpretable.</population>
        <group_list>
          <group group_id="O1">
            <title>SSP-004184SS (Fed)</title>
            <description>21.8 mg/kg (oral capsule form) given once on Day 1 under fed conditions.</description>
          </group>
          <group group_id="O2">
            <title>SSP-004184SS (Fasted)</title>
            <description>21.8 mg/kg (oral capsule form) given once on Day 1 under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUCinf) of SSP-004184 Under Fasted and Fed Conditions</title>
          <description>AUCinf is the area under the plasma concentration versus time curve from time 0 to infinity. AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.</description>
          <population>Pharmacokinetic Set: All subjects in the Safety Set for whom the primary pharmacokinetic data were considered sufficient and interpretable.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112,236.7" spread="28,804.8"/>
                    <measurement group_id="O2" value="154,676.6" spread="28,185.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence (legacy)</non_inferiority_type>
            <non_inferiority_desc>The magnitude effect of food on the pharmacokinetic parameters was evaluated by calculating the point estimate and 90% CIs between Treatment A (test treatment, fed) and Treatment B (reference treatment, fasted).</non_inferiority_desc>
            <param_type>Ratio of Geometric LS Means</param_type>
            <param_value>0.718</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.670</ci_lower_limit>
            <ci_upper_limit>0.770</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measureable Concentration (AUClast) of SSP-004184 Under Fed and Fasted Conditions</title>
        <description>AUClast is the area under the curve from the time of dosing to the last measurable concentration. AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.</description>
        <time_frame>Study Periods 1 &amp; 2: Within 30 minutes pre-dose, and Post-dose 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 48, 72 hours.</time_frame>
        <population>Pharmacokinetic Set: All subjects in the Safety Set for whom the primary pharmacokinetic data were considered sufficient and interpretable.</population>
        <group_list>
          <group group_id="O1">
            <title>SSP-004184SS (Fed)</title>
            <description>21.8 mg/kg (oral capsule form) given once on Day 1 under fed conditions.</description>
          </group>
          <group group_id="O2">
            <title>SSP-004184SS (Fasted)</title>
            <description>21.8 mg/kg (oral capsule form) given once on Day 1 under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measureable Concentration (AUClast) of SSP-004184 Under Fed and Fasted Conditions</title>
          <description>AUClast is the area under the curve from the time of dosing to the last measurable concentration. AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.</description>
          <population>Pharmacokinetic Set: All subjects in the Safety Set for whom the primary pharmacokinetic data were considered sufficient and interpretable.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112,066.1" spread="28,822.9"/>
                    <measurement group_id="O2" value="154,446" spread="28,066.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence (legacy)</non_inferiority_type>
            <non_inferiority_desc>The magnitude effect of food on the pharmacokinetic parameters was evaluated by calculating the point estimate and 90% CIs between Treatment A (test treatment, fed) and Treatment B (reference treatment, fasted).</non_inferiority_desc>
            <param_type>Ratio of Geometric LS Means</param_type>
            <param_value>0.718</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.670</ci_lower_limit>
            <ci_upper_limit>0.769</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax) of SSP-004184 Under Fed and Fasted Conditions</title>
        <description>Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated.</description>
        <time_frame>Study Periods 1 &amp; 2: Within 30 minutes pre-dose, and Post-dose 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 48, 72 hours.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SSP-004184SS (Fed)</title>
            <description>21.8 mg/kg (oral capsule form) given once on Day 1 under fed conditions.</description>
          </group>
          <group group_id="O2">
            <title>SSP-004184SS (Fasted)</title>
            <description>21.8 mg/kg (oral capsule form) given once on Day 1 under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of SSP-004184 Under Fed and Fasted Conditions</title>
          <description>Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32,755.6" spread="11,797.4"/>
                    <measurement group_id="O2" value="70,733.3" spread="9,782.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence (legacy)</non_inferiority_type>
            <non_inferiority_desc>The magnitude effect of food on the pharmacokinetic parameters was evaluated by calculating the point estimate and 90% CIs between Treatment A (test treatment, fed) and Treatment B (reference treatment, fasted).</non_inferiority_desc>
            <param_type>Ratio of Geometric LS Means</param_type>
            <param_value>0.449</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.380</ci_lower_limit>
            <ci_upper_limit>0.530</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>SSP-004184SS (Fed)</title>
          <description>21.8 mg/kg (oral capsule form) given once on Day 1 under fed conditions.</description>
        </group>
        <group group_id="E2">
          <title>SSP-004184SS (Fasted)</title>
          <description>21.8 mg/kg (oral capsule form) given once on Day 1 under fasted conditions.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Chromaturia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Shire</organization>
      <phone>+1 866 842 5335</phone>
      <email>ClinicalTransparency@shire.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

